Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hoursEarly Subcutaneous Insulin Shortens Recovery Time for Diabetic Ketoacidosis

Endocrinology, diabetes & metabolism Published July 7, 2026 Study authors: AbuJlambo Abdallah, AbuZarifa Maha, Sawh Rejean R R, Narayana Reddy N Subhash Reddy, Salman Muhammad… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider adding early subcutaneous basal insulin to IV therapy to reduce time to DKA resolution by 4.06 hours.

This meta-analysis synthesized data from randomized controlled trials involving 407 adults with diabetic ketoacidosis (DKA) to evaluate the impact of adding early subcutaneous (SC) basal insulin to standard intravenous (IV) insulin therapy. The primary outcome, time to DKA resolution, showed a significant reduction of 4.06 hours (95% CI -5.53 to -2.58; p < 0.0001).

Secondary outcomes included total fluid requirements, which decreased by approximately 400 mL. However, the authors noted that the clinical significance of this reduction in fluid requirement was modest. Other secondary measures, including hospital length of stay, rebound hyperglycemia, recurrent DKA, hypoglycemia, hypokalemia, and mortality, showed no significant differences between the groups.

Safety profiles were comparable between the intervention and comparator groups, with no significant differences reported for hypoglycemia, rebound hyperglycemia, or electrolyte disturbances such as hypokalemia. These findings suggest that early SC basal insulin can accelerate resolution of DKA in adults without increasing common complications, though the impact on overall hospital stay duration is not established.

How this fits prior evidence

This meta-analysis addresses a gap in managing acute diabetic emergencies by evaluating specific insulin delivery methods for DKA. It builds upon existing knowledge regarding the risks of SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk and the high mortality rates observed in various settings for patients with DKA.

Researchers analyzed data from 407 adults with diabetic ketoacidosis (DKA) to see if adding a specific type of insulin helped treatment. They compared using only intravenous (IV) insulin against a combination of IV insulin and early subcutaneous (SC) basal insulin.

The results showed that patients who received both types of insulin saw their condition resolve significantly faster, with a reduction in time of about 4 hours. The study also found that this method reduced the total fluid requirement by approximately 400 mL. However, there were no significant differences in the length of hospital stays for either group.

Safety was a key part of the review. The researchers found no significant differences in risks like low blood sugar (hypoglycemia), rebound high blood sugar, or electrolyte issues like low potassium (hypokalemia). While the reduction in fluid needs was noted as modest, the main finding is that adding subcutaneous insulin can speed up recovery time. Patients and doctors should discuss these findings to determine the best treatment plan.

What this means for you:

Adding early subcutaneous insulin to IV therapy may speed up DKA resolution without increasing common safety risks.

Common questions

Does adding subcutaneous insulin make the treatment safer?

The study found no significant differences in safety risks when comparing the two methods. Specifically, there were no significant differences in cases of hypoglycemia (low blood sugar), rebound hyperglycemia, or electrolyte disturbances like hypokalemia.

How much faster does it resolve DKA?

Patients who received both IV and early subcutaneous basal insulin saw their condition resolve significantly faster. The data showed a reduction in the time to resolution of approximately 4 hours compared to those receiving only IV insulin.

Does this treatment change how long patients stay in the hospital?

The study found no significant differences in the length of hospital stay for patients who received either the combination therapy or just IV insulin alone. The primary benefit noted was the faster time to resolution of the condition.

Study Details

Study typeMeta analysis

Sample sizen = 407

EvidenceLevel 1

PublishedJul 2026

PMID42405473

View Original Abstract ↓

BACKGROUND: Diabetic ketoacidosis (DKA) is a life-threatening metabolic emergency requiring prompt insulin therapy. Although intravenous (IV) insulin infusion remains the standard treatment, early initiation of subcutaneous (SC) basal insulin during IV therapy may improve outcomes. We evaluated the efficacy and safety of early basal insulin administration in adults with DKA. METHODS: A systematic review and meta-analysis following PRISMA 2020 guidelines searched PubMed, Embase and Cochrane Library from inception to February 2026 for randomised controlled trials (RCTs) comparing early SC basal insulin plus IV insulin versus IV insulin alone in adults with DKA. Primary outcomes were time to DKA resolution and hospital length of stay. Secondary outcomes included total fluid requirement, hypoglycaemia, rebound hyperglycaemia, recurrent DKA, electrolyte disturbances and mortality. Meta-regression explored sources of heterogeneity. RESULTS: Eight RCTs involving 407 participants were included. Early basal insulin significantly reduced time to DKA resolution (MD -4.06 h, 95% CI -5.53 to -2.58; p < 0.0001; I = 56.3%), with consistent findings in sensitivity analysis (MD -3.44 h; I = 0%). Total fluid requirements decreased by approximately 400 mL, although clinical significance was modest. No significant differences were observed in hospital length of stay, rebound hyperglycaemia, recurrent DKA, hypoglycaemia, hypokalaemia, or mortality. Meta-regression showed no significant effect modification by age, BMI, sample size, or male proportion. CONCLUSIONS: Early SC basal insulin combined with IV insulin significantly shortens DKA resolution time and modestly reduces fluid requirements without increasing adverse events. While no significant effects were observed on hospital stay or recurrence outcomes, these findings support the safety and potential clinical benefit of early basal insulin use in DKA management. Larger multicentre trials are warranted.

Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hoursEarly Subcutaneous Insulin Shortens Recovery Time for Diabetic Ketoacidosis

How this fits prior evidence

Common questions

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hoursEarly Subcutaneous Insulin Shortens Recovery Time for Diabetic Ketoacidosis

How this fits prior evidence

Common questions

More on Diabetic Ketoacidosis

Study Details

Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis

New analysis links diabetes drugs to liver outcomes in millions of patients

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties